Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$AGBA - Since going public via a SPAC in November 2023, AGBA's team of over 1,500+ employees has worked tirelessly everyday in delivering steady growth persistently quarter after quarter maintaining our market leadership.
https://finance.yahoo.com/news/empowering-shareholders-agbas-us-4b-130000814.html
$RWGI is excited to announce the expansion of its Tree Moguls™ brand into retail cannabis dispensaries and cannabis delivery services. https://finance.yahoo.com/news/rodedawg-otc-rwgi-expands-tree-120000717.html
$VTAK Catheter Precision, Inc. (VTAK) Announces Receipt of New Purchase Order and Product Evaluation at New Hospital
https://finance.yahoo.com/news/catheter-precision-inc-vtak-announces-130000257.html
AI-Powered Vending Machines coming soon at $CBIA https://twitter.com/BlueHeavenCafe/status/1786074952782782691
$AURI U.S. Drug Control Agency Moves to Reclassify Marijuana in a Historic Shift That Would Benefit Auri Inc. and Knockout Gummies Brand
https://www.newmediawire.com/news/u-s-drug-control-agency-moves-to-reclassify-marijuana-in-a-historic-shift-that-would-benefit-auri-inc-and-knockout-gummies-brand-7074637
$CBIA AI VENDING MACHINES - COMING SOON... hhttps://twitter.com/BlueHeavenCafe/status/1786074952782782691
$NRXP News: NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression
Both drugs demonstrated > 50% response for treating depression. NRX-101 demonstrated a mean 76% reduction in symptoms of akathisia compared to lurasidone that was sustained over 42 days (Effect Size .37; P=0.025), using prespecified analytic methodology memorialized in FDA Special Protocol Agreement. Levels of akathisia with NRX-101 were essentially zero at day 42
This safety advantage was previously reported in the Company's published STABIL-B trial
Akathisia is identified as a life-threatening side effect of nearly all antidepressants, reported in 10-15% of treated patients and is closely linked to suicide in FDA black box warning
Akathisia was seen in 2% of participants treated with NRX-101 vs. 11% treated with lurasidone
Company plans to seek accelerated approval of NRX-101 for use in patients with bipolar depression at risk of akathisia while continuing to broaden the indication to all patients with bipolar depression and perhaps schizophrenia
Study will be presented at the American Society of Clinical Psychopharmacology (ASCP) meeting May 28-31, 2024 (Miami) together with study investigators, accompanied by a broadcast scientific presentation on akathisia and antidepressant safety, and investor Q&A
RADNOR, Pa., May 6, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical stage pharmaceutical company, today announced a statistically significant safety advantage of NRX-101 compared to the standard of care comparator in its recently completed clinical trial in patients with suicidal bipolar depression. Therefore, the Company believes that demonstration of reduced akathisia in the setting of comparable antidepressant efficacy constitutes a basis for Accelerated FDA Approval of NRX-101. The full clinical trial results will be presented at the upcoming meeting to the American Society of Clinical Psychopharmacology held May 28-31, 2024 in Miami. NRx will gather Key Opinion Leaders to educate the public on the importance and potentially life-saving implication of this finding.
Last week, the Company released preliminary top-line data as required by SEC disclosure rules. The Company believes that today's findings based on mixed model regression analysis as specified in the Company's Special Protocol Agreement with the FDA, when combined with the prior STABIL-B trial1, demonstrate a basis for seeking accelerated drug approval of NRX-101 based on improved safety related to akathisia and suicidality in the setting of comparable antidepressant efficacy.
Trial participants had identical mean scores on the Barnes Akathisia Rating Scale (BARS) at baseline with subsequent decrease in the NRX-101 treated group versus an increase in the lurasidone-treated group, yielding a 76% relative mean difference between the groups. The difference was apparent at the first post-randomization visit and continued throughout the trial. (Fig 1) Over the 42 days of observation, an effect size of .37 was identified with a statistically significant P value of 0.025 on the Mixed Model for Repeated Measures (MMRM) methodology agreed to with FDA in the 2018 Special Protocol Agreement. Akathisia as ascertained by a 1 point increase in the BARS was seen in 11% of participants randomized to lurasidone (comparable to previous reports in the literature) and seen in only 2% of those treated with NRX-101, an akathisia level that was previously reported for the placebo arm of the lurasidone registration trial.
Akathisia was a prespecified key safety endpoint of the Company's clinical trial. Hence this finding is not a "post-hoc" observation. As previously noted, this clinical trial of 91 participants with suicidal bipolar depression who were not pre-treated with ketamine demonstrated that NRX-101 and lurasidone were comparable in their antidepressant effect. A 33% but statistically non-significant sustained decrease in suicidality was also seen favoring NRX-101. As noted above, improved antidepressant efficacy is not required to seek drug accelerated drug approval based on a statistically-significant safety benefit.
Based on this safety finding, NRx plans to seek Accelerated Approval of NRX-101 for treatment of bipolar depression in patients at risk for akathisia who are at highest risk of suicide, while continuing to develop evidence to support broader indications both in treatment of depression and schizophrenia. Should these data be confirmed in additional large scale trials, the Company believes that physicians and patients will universally prefer antidepressant and antipsychotic drugs with a reduced akathisia risk. The NRx patent portfolio supports the development of a broad range of combined NMDA/serotonergic drugs for treatment of depression and psychosis.
There is a recent regulatory precedent for the approval of psychiatry drugs that demonstrate comparable efficacy with improved safety. A combination of olanzapine and samidorphan (LYBALVI®) was approved based on comparable effect on schizophrenia symptoms with evidence of less weight gain favoring LYBALVI. Thus, public assertions by journalists and short-sellers that NRx has no path to market based on the finding of comparable efficacy in this trial are utterly baseless and may be designed to mislead investors.
"More than 7 million Americans suffer from bipolar depression with a potential market opportunity in excess of $20 billion. No prior drug to treat bipolar depression has demonstrated superiority on side effects most closely linked to suicide. Patients with bipolar depression have a 50% lifetime risk of a suicidal attempt and a 20% lifetime risk of dying from suicide. On this basis of these superiority findings, previously seen in the STABIL-B trial, we plan to seek Accelerated Approval from FDA for treatment of patients with bipolar depression who are at risk for akathisia, as we and our partners continue to broaden the indication to the treatment of all patients with bipolar depression." said Dr. Jonathan Javitt, NRx's Chairman and Chief Scientist. "Patients and key opinion leaders alike have told us clearly that an antidepressant with comparable antidepressant effect and reduced risk of akathisia and other risk factors for suicidality would be unambiguously preferred in the marketplace."
Background on Akathisia
Akathisia is a known extrapyramidal side effect of all serotonin-targeted antidepressants and antipsychotic drugs. It can be demonstrated in laboratory models, using rodent behavioral data.2 Prof. Daniel Javitt, the inventor of NRX-101 first discovered the ability of NMDA antagonist drugs to reduce akathisia in 2009, which forms the basis of the Company's composition of matter patent portfolio. In his 2012 patent application Javitt stated 3
A major limitation in use of antipsychotic and antidepressant medications is the liability to produce behavioral side effects, especially anxiety, agitation, and akathisia, all of which are associated with generating or exacerbating suicidality in psychotic or depressed patients. These behavioral side effects can be differentiated from symptoms of the illness by consideration of both time course and specific patterns of symptoms.
The side effect is clearly recognized in an FDA-mandated black box warning applied to lurasidone and all medications in its class of drugs, with a specific warning about suicidality as follows:
"The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and non-psychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality"4.
In most clinical trials, safety endpoints are not a basis for drug approval, although adverse safety findings may prevent drug approval. Typically, new drugs are compared to placebo in order to prove a difference in efficacy. In this case, the trial was conducted against the standard of care drug, not against placebo and, therefore, safety differences are highly important. Akathisia is a labeled negative side-effect of lurasidone and all similar drugs, and is closely linked to suicidal behavior.56 It is a side effect about which patients must be warned[7] and has figured prominently in class action lawsuits brought against manufacturers of serotonin-targeted antidepressants and antipsychotics. Currently, there is no FDA-approved treatment for akathisia and it is considered a medical emergency by many treating psychiatrists. Akathisia causes extreme anxiety to patients, inability to control motor movement, and impulsive acts, all to often leading to suicide and may be the key driver of the observed increase in suicidal ideation and behavior associated with all serotonin-targeted antidepressants and antipsychotic drugs.
"These studies support our original observation that D-cycloserine reverses the akathisia-like behaviors induced by lurasidone in rodent models. It is exciting to see those findings demonstrated in a second trial with unequivocal statistical significance," said Prof. Daniel Javitt, co-founder of NRx Pharmaceuticals. "Hopefully, this opens a path to bringing a lifesaving drug to millions of patients with suicidal depression whose only approved long-term treatment is electroconvulsive therapy."
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
1 Nierenberg A, Lavin P, Javitt DC, et. al. NRX-101 vs lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior; a randomized prospective phase 2 trial. Int J Bipolar Dis 2023;11:28-38, doi.org/10.1186/s40345-023-00308-5
2 Walf, A. A., & Frye, C. A. (2007). The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nature Protocols, 2(2), 322-328. https://doi.org/10.1038/nprot.2007.44
3 Javitt DC. Composition and method for treatment of depression and psychosis in humans. US Patent 10583138B2. Granted March 10, 2020.
4 Trivedi et al., J Clin Psychiatry, 72:765-774, 2011
5 Chow LC, Kahouh NK, Bostwick JR, et. al., Akathisia and newer second-generation antipsychotic drugs: A review of current evidence. Pharmacotherapy 202;40(6):565-574 doi: 10.1002/phar.2404
6 Uwai Y, Nabekura T. Risk factors for suicidal behavior/ideation and hostility/aggression in patients with bipolar disorders: An analysis using the Japanese adverse drug event report database. J Psychiatric Res 2022;153:99-103. https://doi.org/10.1016/j.jpsychires.2022.07.005
7 https://www.webmd.com/schizophrenia/side-effects-of-lurasidon
https://c212.net/c/img/favicon.png?sn=CL05849&sd=2024-05-06 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-announces-final-clinical-trial-results-superior-safety-combined-with-similar-efficacy-in-the-trial-of-nrx-101-compared-to-lurasidone-in-suicidal-bipolar-depression-302136430.html
SOURCE NRx Pharmaceuticals, Inc.
$CBDW - Why Now is the Time to Invest in AI Technology https://cbdw.ai/why-now-is-the-time-to-invest-in-ai-technology/
$CBIA Leveraging the success of its AI-powered digital vending machines, BHC has unveiled a pioneering loyalty initiative tailored exclusively for users of its unattended retail network across North America. Leveraging the success of its AI-powered digital vending machines, BHC has unveiled a pioneering loyalty initiative tailored exclusively for users of its unattended retail network across North America.
$TKMO SO UNDER VALUED STOCK
By end of December 2023
ASSETS: $3,914,178
REVENUES: $2,691,950
$PDGO - In this regard, the related entity has executed several new Letters of Intent for additional acquisitions in furtherance of the Company's strategy. The related entity is presently engaged in the diligence necessary to bring the Letters of Intent to contract and closing.
https://www.otcmarkets.com/stock/pdgo/news/Paradigm-Oil--Gas-Inc-PDGO-Expands-Market-Presence-with-Proposed-Strategic-Oil-and-Gas-Acquisitions?id=439005
$NCL News: Northann Corp.'s Blue11-Ocean Plastic Flooring and Wall Panels Product Wins Multiple Prestigious Awards in 2024
ELK GROVE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Northann Corp. (NYSE American: NCL), a leader in innovative sustainable solutions, today announced that its Blue11-Ocean Plastic Flooring and Wall Panels Product has been recognized this year with industry awards for outstanding design, commitment to sustainability, and impeccable craftsmanship.
These awards include:
American Good Design Award 2024
French Design Award 2024
IDA Design Awards 2024
New York Product Design Awards
Green Product Award
Best Surfaces in TISE 2024
"We are truly honored to receive these prestigious awards, which underscore our commitment to creating products that are not only visually captivating but also environmentally conscious," remarked Northann Corp. CEO Lin Li. "This recognition fuels our passion to continue delivering innovative and sustainable solutions that resonate with our customers and contribute positively to the environment.
“Northann Corp.'s Blue11-Ocean Plastic Flooring and Wall Panels Product stands as a shining example of our company's enduring pursuit of excellence and sustainability.”
To learn more about this award-winning product and Northann Corp.'s comprehensive range of sustainable solutions, please visit www.northann.com and www.benchwick.com.
About Northann Corp.
Northann specializes in 3D-printed flooring solutions under its flagship brand, "Benchwick." The Company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers its 3D printing ecosystem as an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe. The Company aims to redefine the essence of modern flooring and wall panels by offering stylish, durable, and ecologically conscious solutions.
For more information about Northann, please visit http://www.northann.com.
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For investor and media inquiries, please contact:
Investor Relations
Northann Corp.
Email: ir@northann.com
Phone: +1 (916) 573-3803
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor New York, NY, 10036
Office: (646) 893-5835 x2
Email: info@skylineccg.com
$DTII Defense Technologies International Corp. (DTII): The Science and Technology Directorate of U.S. Department of Homeland Security invites DTII to their Test Program
https://finance.yahoo.com/news/defense-technologies-international-corp-dtii-130000071.html
$NRXP News: NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression
NRX-101 is first oral antidepressant to show 33% advantage in sustained remission in suicidality (not statistically significant at this sample size) and 75% advantage in relief from Akathisia relative to lurasidone - never previously shown with an oral antidepressant. Suicidality signal met the study's promising zone criteria and the akathisia signal approached statistical significance (P=0.076)
Both NRX-101 and lurasidone, an accepted standard of care in Bipolar Depression, demonstrated approximately 50% reduction in symptoms of depression
These data are comparable to previous statistically-significant finding of reduced suicidality and in the published STABIL-B trial and support an approval pathway via a 300-person registrational trial with sustained remission in suicidality as the primary endpoint
Company believes that an oral antidepressant that demonstrates reduction in suicidality has potential to become standard of care for treatment of bipolar depression.
Data from this study expand the potential utility of NRx-101 to treat both patients with suicidal bipolar depression (who will require prior use of ketamine) and those without subacute suicidality (nearly 7 million patients in the US).
RADNOR, Pa., April 30, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical stage pharmaceutical company today that its Breakthrough Therapy designated investigational drug NRX-101 vs lurasidone demonstrated a promising, though not yet statistically significant 33% reduction in suicidality together with a 70% reduction (P=.076) reduction in symptoms of akathisia – a side effect of antidepressants that is closely linked to suicide and considered a medical emergency. Because of the high-risk nature of these patients, a placebo group could not be employed, and NRX-101, a fixed dose combination of D-cycloserine (DCS) and lurasidone, was compared to lurasidone alone (the standard of care). In the Company's previously published STABIL-B trial (STABIL-B), NRX-101 was demonstrated to be superior to lurasidone in reducing both depression and suicidality after ketamine while showing a trend towards reducing akathisia (a side effect involving restlessness and agitation that is considered a warning sign of impending suicide). In this trial, without prior use of ketamine, NRX-101 and lurasidone were comparable in their effect on depression. The trial was a randomized, prospective, double-blind study conducted at multiple sites in the Unites States whose protocol and statistical analysis plan may be viewed on www.clinicaltrials.gov (NCT03395392).
"We are gratified by these results, which extend the findings of the STABIL-B trial in suggesting that NRX-101 has the potential to be the first oral antidepressant to decrease potential for suicide, whereas all currently approved oral antidepressants are known to increase the risk of suicide," said Prof. Jonathan Javitt, MD, MPH, the Company's Chairman and Chief Scientist. "Should these findings be confirmed in a registrational trial of 300 patients, NRX-101 has the potential to represent a paradigm-changing blockbuster drug. The finding of a dramatic difference in akathisia was also seen in the STABIL-B trial and provides important mechanistic support for the difference seen on the Columbia Suicide Severity Rating Scale. Many of the patients who tragically die from suicide in bipolar depression are taking traditional antidepressants at the time of their death, a tragedy we have seen within the families of our investors and board members, as well as the many patients we have known. If today's findings are replicated in a registration-sized trial, we will change the world for patients who currently have a 50% lifetime risk of suicide attempt, a 20% lifetime risk of death by suicide, and whose only approved treatment option today is electroshock therapy."
"These findings are consistent with our original Phase 2 objectives and promising zone methodology in terms of a demonstrable advantage of NRX-101 compared to the standard of care in treating patients with bipolar depression who are known to be at high risk of suicide. We originally proposed to test suicidality, rather than depression as the primary endpoint for this trial and took the advice of senior FDA leadership that demonstrating a difference in suicidality might be too challenging. Today's findings demonstrate that differences in suicidality and akathisia can be demonstrated compared to best available antidepressant therapy in a properly sized registration trial and that superiority over placebo on the depression scale may readily be demonstrated in a less acute patient population where it would be safe to do so," said Dr. Philip Lavin, the study's Lead Methodologist. Dr. Lavin is one of the world's most widely published statisticians who has led the approval/clearance of more than 80 drugs, devices, and biologics.
In the current study, without prior use of ketamine, NRX-101 and lurasidone exhibited comparable antidepressant effects, each reducing depression (the primary endpoint) on the Montgomery Asberg Depression Rating Scale (MADRS) by about 50% from baseline. Lurasidone is known to reduce symptoms of depression by approximately 4 points in multiple registration trials compared to placebo.
Analysis of suicidality using the Columbia Suicide Severity Rating Scale (C-SSRS) demonstrated a sustained 33% advantage in remission from suicidality favoring NRX-101 (see figure). This difference was not statistically significant at the phase 2 sample size but met the study's original promising zone criteria and, if sustained in a registration trial of 300 or more patients, would be powered to yield a statistically significant result. The reduction in suicidality is comparable to that demonstrated after ketamine, both in the Company's STABIL-B trial and in an independently conducted trial comparing DCS to placebo after ketamine (Chen, et. al.). A meaningful remission in suicidality has not been demonstrated with any prior oral antidepressant drug – indeed, antidepressant drugs carry a Black Box warning of increased suicide risk.
Reduction in akathisia was first identified in the laboratory as a distinguishing feature of DCS and is the basis of the approved claims in the Company's Composition of Matter patents. Akathisia is often characterized as a state of agitation and motor restlessness that is associated with particularly impulsive and tragically effective attempts at suicide, such as hanging, shooting, jumping from buildings and in front of vehicles and trains. In this trial, a 75% relative difference was seen on the Barnes Akathisia Rating Scale (BARS), with two-sided P=0.076, which would be expected to achieve significance in a properly powered registration-sized trial. While reduction in akathisia is not proposed as a primary labeled indication, continued finding of a statistically significant reduction in this side effect would be highly supportive of a demonstrated primary endpoint of reduced suicidality and would provide clinical corroboration.
Based on these findings and widespread adoption of ketamine as initial treatment for suicidal depression, the Company believes that NRX-101 may become the drug of choice for potentiating the effect of ketamine in patients with acute and subacute suicidality. The FDA recently affirmed to the Company that the Special Protocol Agreement for this indication remains in place, subject to the Company filing a New Drug Approval for ketamine, which is expected by July 2024. Moreover the Company aims to explore the role of NRX-101 as primary treatment for the much larger population (approximately 7 million in the US) of patients with bipolar depression who do not have active suicidality and, therefore, do not require prior treatment with intravenous ketamine.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
https://c212.net/c/img/favicon.png?sn=CL01020&sd=2024-04-30 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-announces-promising-findings-in-phase-2b3-clinical-trial-of-nrx-101-vs-lurasidone-for-treatment-of-suicidal-bipolar-depression-302131482.html
SOURCE NRx Pharmaceuticals
Dive into the future of e-commerce with $CBDW and see the direct impact of AI on your investment. https://www.linkedin.com/posts/greg-lambrecht_ai-ecommerce-investment-activity-7190681244194541568-vCo3?utm_source=share&utm_medium=member_desktop
$PDGO News April 15, 2024
PDGO Announces Acquisition
https://www.otcmarkets.com/stock/PDGO/news/PDGO-Announces-Acquisition?id=436678
$AURI News April 25, 2024
Riddick Bowe the Knockout Brand Ambassador for AURI
https://www.otcmarkets.com/otcapi/company/dns/news/document/74158/content
$RENB News: RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership
LOS ANGELES and AMSTERDAM, April 24, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a trailblazer in AI-driven early cancer diagnostics and therapeutics, and Cyclomics, a leader in ultra-sensitive 4th generation multi-omics molecular biology, proudly announce a significant milestone in their collaboration. RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment. Their combined relationships with Oxford Nanopore and Nvidia will further position RenovaroCube to be a leader in early cancer diagnostics and monitoring of treatment efficacy. Oxford Nanopore is a leader in sequencing technologies and Nvidia will provide vital super computing power and front edge software solutions such as Parabricks, BioNeMo, Monai and Nemo.
Initially set at a 75% acquisition, this decision to acquire the remaining 25% of Cyclomics reflects the resounding success of their partnership and the remarkable synergy between the two companies. Upon closing, we believe the acquisition of Cyclomics into the Renovaro family will further strengthen our ability to create a powerhouse for cancer diagnostics throughout the entire patient journey, from early detection/recurrence and personalized treatment in late-stage disease. "We believe that this combination can transform the landscape of patient care both for early detection as well as for monitoring continuously the therapeutics given,” according to Dr. Coenraad K. van Kalken (MD/PHD), Chief Commercial Officer of RenovaroCube.
RenovaroCube's open architecture Artificial Intelligence platform, known as the Cube, currently houses over 3600 high-performance biomarker panels for 13 different cancers. This molecular differential AI platform utilizes multi-omic analysis combined with proprietary algorithms and when coupled with Cyclomics' groundbreaking 4th generation molecular technology, shall be able to decode multi-omic data from just a single vial of blood. "We will work with Cyclomics from ‘strength to strength’ providing combined technologies, expertise, and resources which will make us unique and offers what we believe will be an unprecedented accuracy in non-invasive early cancer detection,” added Dr. Henk Viëtor (MD/PHD).
Cyclomics has pioneered a groundbreaking diagnostic method named ‘CyclomicsSeq’ for monitoring early cancer recurrence, utilizing Oxford Nanopore sequencing technology they have created an assay in partnership with Oxford Nanopore that provides detection of even a single ctDNA molecule in blood with nearly 100% accuracy. Additionally, Cyclomics' OmniOmics 4th generation technology enables reliable, fast, and ultra-sensitive early detection of cancer or recurrence thereof using next-generation whole genome sequencing.
"We are excited to join forces with Renovaro to drive the next wave of innovation in molecular biology integrated into an advanced proprietary AI/ML platform," commented Alessio Marcozzi, CSO of Cyclomics. "This combination reflects our shared commitment to pushing the boundaries of what is possible in our respective fields."
About Renovaro:
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes Renovaro Bio with its advanced cell-gene immunotherapy company and RenovaroCube. RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Upon the closing of the acquisition of Cyclomics (winner of the Health Holland Venture Challenge), RenovaroCube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This has the potential to transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.
The combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
https://www.globenewswire.com/newsroom/ti?nf=OTEwNDIyNSM2MjEzNzA2IzIxMjA2Nzk=
https://ml.globenewswire.com/media/ODIwZWYyMTctYWIzMi00MmZiLTk5ZjctMjQ0YTEwMDUxMGMwLTExMzIyNTA=/tiny/Renovaro-Inc.png
Source: Renovaro Inc
$PDGO News December 28, 2023
Paradigm Oil And Gas, Inc. Announces Change in Control and Letter of Intent
https://www.otcmarkets.com/stock/PDGO/news/Paradigm-Oil-And-Gas-Inc-Announces-Change-in-Control-and-Letter-of-Intent?id=425854
$NCL News: Northann Corp Enters Strategic Relationship with Rexil Group of Companies Netherlands to Promote Sustainable Technology and Products
ELK GROVE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Northann Corp (NYSE American: NCL), a leading innovator in 3D-printed home improvement solutions, is pleased to announce the signing of a strategic relationship with Golden Gate BCE B.V., a subsidiary of Rexil Group of Companies Netherlands, a prominent distributor in the Netherlands. This collaboration aims to enhance the presence of sustainable technology and products throughout Rexil Group of Companies Netherlands and its subsidiaries distribution channels.
Under this agreement, Rexil Group of Companies Netherlands will promote Northann Corp's environmentally friendly products, Blue11 and SuperOak, to its extensive network of customers in the Netherlands. This partnership aligns with Northann Corp's commitment to sustainability and innovation, furthering its mission to transform spaces through cutting-edge solutions.
"We are thrilled to partner with Rexil Group of Companies Netherlands to bring our sustainable technology and products to a wider audience in the Netherlands," said Lin Li, CEO and President of Northann Corp. "This collaboration underscores our dedication to environmental stewardship and showcases our commitment to providing innovative solutions to our customers."
Northann Corp’s partnership with Rexil Group of Companies Netherlands represents a significant step forward for the Company in its efforts to expand its global presence and promote sustainable practices within the industry. Both companies share a common vision for driving positive change through innovation and sustainability, making this a synergistic collaboration for both parties.
About Northann Corp.
Northann specializes in 3D-printed flooring solutions under its flagship brand, "Benchwick." The Company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers its 3D printing ecosystem as an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe. The Company aims to redefine the essence of modern flooring and wall panels by offering stylish, durable, and ecologically conscious solutions.
For more information about Northann, please visit www.northann.com.
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For investor and media inquiries, please contact:
Investor Relations
Northann Corp.
Email: ir@northann.com
Phone: +1 (916) 573-3803
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor New York, NY, 10036
Office: (646) 893-5835 x2
Email: info@skylineccg.com
https://www.globenewswire.com/newsroom/ti?nf=OTEwNDg4NiM2MjE2NTUyIzIyNTM4NDA=
https://ml.globenewswire.com/media/MjQ2NTdjZDQtMDFkMS00NjI4LWE0MTEtZDZkOTEzYjA1ZDkzLTEyNjUzOTM=/tiny/Northann-Corp-.png
Source: Northann Corp.
$INBS Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Third Quarter and Nine-Month Revenue Results
https://www.globenewswire.com/news-release/2024/04/18/2865397/0/en/Intelligent-Bio-Solutions-Inc-Announces-Preliminary-Unaudited-Fiscal-Third-Quarter-and-Nine-Month-Revenue-Results.html
$AGBA News February 15, 2024
AGBA Celebrates Major Milestone with Successful Completion of Private Placement at a Premium to Market Price
https://finance.yahoo.com/news/agba-celebrates-major-milestone-successful-140000317.html
$NCL News: Northann Corp.'s Benchwick Brand to Showcase SuperOak Hybrid Wood Planks Alongside Blue11 Collection at NWFA in New Orleans, April 16-18, 2024
ELK GROVE, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Northann Corp. (NYSE American: NCL) today announced that its Benchwick brand will unveil its latest patented innovation, SuperOak Hybrid Wood Planks, before showcasing its award-winning Blue11 Collection, at the National Wood Flooring Association (NWFA) Expo in New Orleans, April 16-18, 2024, at the New Orleans Ernest N. Morial Convention Center - Hall F & G.
Combining the natural beauty of wood with the durability and sustainability of modern materials, SuperOak Hybrid Wood Planks represent a breakthrough in flooring technology. The product will be in stock across the U.S. starting in May, ensuring customers have access to this revolutionary flooring solution.
"We are thrilled to introduce our Benchwick SuperOak Hybrid Wood Planks, as well as showcase our award-winning Blue11 Collection, at NWFA," said Lin Li, CEO and President of Northann Corp. "SuperOak demonstrates our dedication to pushing the boundaries of flooring technology."
Attendees of NWFA are invited to visit Northann at booth number 2219 to explore the SuperOak and Blue11 Collection and learn more about Benchwick's cutting-edge flooring solutions.
For more information about Northann Corp. and its Benchwick brand, visit www.northann.com.
About Northann Corp.
Northann specializes in 3D-printed flooring solutions under its flagship brand, "Benchwick." The Company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers its 3D printing ecosystem as an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe. The Company aims to redefine the essence of modern flooring and wall panels by offering stylish, durable, and ecologically conscious solutions.
For more information about Northann, please visit www.northann.com.
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For investor and media inquiries, please contact:
Investor Relations
Northann Corp.
Email: ir@northann.com
Phone: +1 (916) 573-3803
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor New York, NY, 10036
Office: (646) 893-5835 x2
Email: info@skylineccg.com
https://www.globenewswire.com/newsroom/ti?nf=OTA4OTg3MCM2MjAyMzk1IzIyNTM4NDA=
https://ml.globenewswire.com/media/ZWViZDNhYWYtNmMzYS00OGZiLTlmNjItMGI4MTE3NDQ2MTEyLTEyNjUzOTM=/tiny/Northann-Corp-.png
Source: Northann Corp.
$AGBA Highlights
•FLOAT=11M
•CURRENT MARKET CAP=$24M
•INSIDERS OWN 83%
•$555M INITAL LISTING VALUATION
#BreakingNews: $RONN, Inc. Agrees to Work with H2H to Integrate Their Patented Products into Ronn Inc. Global Projects https://finance.yahoo.com/news/ronn-inc-agrees-h2h-integrate-121500419.html
$BIDCF $BITK.V BlockchainK2 Announces Update on Strategic Investment in RealBlocks https://finance.yahoo.com/news/blockchaink2-announces-strategic-investment-realblocks-070000511.html
$PDGO Announces Acquisition of 100% Interest in 58 Oil and Gas Wells and 600 Acres of Land
in Oklahoma https://www.otcmarkets.com/otcapi/company/dns/news/document/73893/content
$NRXP News: NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
Formulation based on prior patents by NRx founder
Achieved pH neutral formulation of ketamine, potentially enabling both intravenous (IV) and subcutaneous (SQ) administration
Company expects Composition of Matter patent protection
Company previously executed joint development agreement with US manufacturer of insulin pumps
RADNOR, Pa., April 15, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced that the Company has developed a novel, proprietary formulation of IV Ketamine for use as HTX-100. This new formulation has the key advantage of achieving neutral pH, in contrast to the acidic pH of generic formulations of ketamine. Acidic substances are tolerated when diluted for intravenous use, but cause pain and may cause skin ulcers if administered subcutaneously. This patentable invention may enable the administration of ketamine in insulin pump-like devices in the clinic setting, eliminating the requirement for intravenous infusion personnel. NeuroRx, Inc. previously executed a joint development agreement with a manufacturer of insulin pumps but has been awaiting a suitable, pH neutral formulation of ketamine.
With this proprietary formulation, developed with our partner Nephron Pharmaceuticals, a leading sterile products manufacturer, NRx is expected to generate one or more patents, such as composition of matter or formulation.
HTX-100 is expected to be marketed by HOPE Therapeutics, Inc., a wholly owned subsidiary of NRx.
"The current formulation of IV Ketamine was developed for battlefield use in the 1960s and has remained relatively static since then. With our new formulation, and Nephron's state of the art manufacturing expertise, we are pleased to be approaching the market with an improved formulation ready for use in modern medicine," said Dr. Jonathan Javitt, Founder, Chairman and Chief Scientist of NRx Pharmaceuticals. "Development of a pH-neutral, subcutaneous form of ketamine administration enables a significantly less complex route of administration in the outpatient setting. Moreover, advances in insulin pump technology create the potential to monitor the brain wave activity and other physiologic parameters associated with ketamine administration and modulate ketamine therapy based on the patient's individual physiologic response."
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (http://www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRx Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
https://c212.net/c/img/favicon.png?sn=CL87341&sd=2024-04-15 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-announces-development-of-new-proprietary-formulation-of-htx-100-iv-ketamine-302116345.html
SOURCE NRx Pharmaceuticals, Inc.
$SHOT News April 08, 2024
$5 Million No Warrants Private Placement Reaffirms Investor Confidence In Safety Shot Inc. (NASDAQ: SHOT)
https://www.marketwatch.com/press-release/5-million-no-warrants-private-placement-reaffirms-investor-confidence-in-safety-shot-inc-nasdaq-shot-fbb40cd1
$AURI Auri Launches a National Wholesale Portal for re-sellers with a new product.
https://www.otcmarkets.com/otcapi/company/dns/news/document/73875/content
$IQST-iQSTEL's FY-2024 Q1 revenue exceeds $50 million based on preliminary accounting. This stock will shoot to $1 once they announce the new acquisition.
https://www.prnewswire.com/news-releases/iqst--iqstel-q1-record-breaking-revenue-exceeds-50m-not-including-recent-acquisition-302114251.html
Read this article - $VVPR still has a bunch of upside.
https://www.nasdaq.com/press-release/does-vivopower-international-nasdaq:vvpr-still-have-more-upside-2024-04-08
$GTVH News: Lavish Entertainment, Inc. Expands Presence in Event Production Industry Through the Acquisition of ABI Create
LAS VEGAS, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN -- Golden Triangle Ventures, Inc. (OTC PINK: GTVH) (“GTV” or the “Company”) is pleased to announce that Lavish Entertainment (or “Lavish”), a wholly owned subsidiary of GTV, has completed a full acquisition of ABI Create (or “ABI”), a premier event management and production firm. Founded in 2015 by Marco Antonio Moreno (recently appointed as the new President and COO of Lavish Entertainment), ABI Create has delivered high-quality productions for a range of large-scale installations at major music festivals, sporting events and conventions across the United States. Notable projects include collaborations with the NFL Super Bowl, San Diego and New York Comic Con, EDC and Camp EDC, Bonnaroo Music Festival, the Waste Management Phoenix Open, Arnold Palmer Invitational, Burning Man, and many more.
This acquisition will transition ABI Create into a wholly owned subsidiary of Lavish Entertainment and bolster its position in the entertainment industry through ABI’s longstanding and exceptional reputation, as well as its proven track record of executing high-level projects. Headquartered in Las Vegas, Nevada, ABI’s comprehensive suite of services includes event organization, management, production, logistics, site planning, permitting, construction, contracting, custom design and fabrication.
Steffan Dalsgaard, CEO of Golden Triangle Ventures, has developed a strong relationship with Marco Moreno through mutual projects, including the production of Lavish Entertainment’s Playa Playground New Year's event ("Playa"), a groundbreaking Burning-Man-style music festival held in Downtown Las Vegas on Dec. 31, 2021. As the relationship progressed, Dalsgaard handpicked Moreno to lead Lavish Entertainment and the development of its Destino Ranch project (www.DestinoRanch.com), as well as leverage ABI Create's expertise to propel Lavish towards its goal of becoming an industry-leading music and arts entertainment production company.
“This acquisition of ABI Create sets the stage for us to begin showcasing all other synergistic divisions within Lavish that will support all resources, relationships and partnerships within the ABI portfolio of offerings,” said Dalsgaard. “Our goal is to develop ABI into a one-stop-shop event management business within Lavish that will hold a complete suite of event management and development services. This aims to complement all internal projects and productions and will potentially support outside business opportunities that can provide fundamental synergies to our ultimate plan of building a complete entertainment enterprise.”
Moreno further comments: “I am excited to deliver my exhaustive portfolio of work and overall business expertise within ABI Create, through Lavish Entertainment. This acquisition marks the first of many exciting commitments and developments that have transpired since my appointment. We are actively working to roll out further details on all other complementary aspects within our revised business model that will evolve Lavish into a powerhouse in the entertainment industry.”
For more information on ABI Create and its team, please visit https://www.abicreate.com/ or follow @marco.a.moreno
About Golden Triangle Ventures, Inc.
Golden Triangle Ventures, Inc. or “GTV” is a multifaceted consulting Company, which operates as the parent business pursuing ventures in the health, entertainment and technology sectors, along with others that provide synergistic value to these three core divisions. The Company aims to purchase, acquire and/or joint venture with established entities within these areas of business. The goods and services represented are driven by innovators who have passion and commitment in these marketplaces. The Company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. The three points of the Golden Triangle exclusively represent the three sectors in which this Company aims to do business. Golden Triangle Ventures is highly focused on acquiring a well-diversified portfolio of companies under one umbrella, which are all managed and owned by the Company. An amazing team of professionals support each division and continue to help the Company grow daily. Being a publicly traded Company gives the ability to provide the support needed to help each subsidiary grow into the business that management believes it can and will become.
Golden Triangle Ventures’ business model is supported by the drive for vertical integration to cut costs and maximize margins. Management strives to acquire entities and assets that they fully understand, which maintain the prospect for long-term exponential growth. The mission is to provide the necessary resources for each subsidiary to generate profit, and then allow them to leverage each other and maximize economic impact. In addition, GTV provides a professional corporate representation service to different companies in these sectors while consulting on a variety of different business development objectives.
The backbone of this business is truly a team of professional advisors looking to help companies with a multitude of corporate objectives. With an extensive Rolodex of relationships, management can help with a dynamic range of project obstacles while maintaining a quality service for each client the Company represents. No matter what the needs are, the team involved can help facilitate many different transactions successfully for all parties involved. The network of relationships expands to industry experts who can assist with project management, product sourcing, industrial agriculture project implementation and so much more. Golden Triangle Ventures develops strategies and detailed plans that are custom-tailored to each corporate need and objective in all areas of business.
The GTV business model is focused on the following core group of interests:
Acquisitions / Assets / Holdings - The Company currently owns a unique portfolio of companies that are all being developed and supported by GTV, each holding a common goal of making a positive impact in the industry in which they operate.
Services - Services are deployed through Golden Triangle Ventures to assist all the unique opportunities within its operation. The Company also offers its services to select opportunities that could develop synergistic value within the relationship between both companies through the result of its efforts.
Investments - Management identifies high-value opportunities and provides capital investments in several companies and projects being developed. Each investment is complemented by a hands-on approach of helping to develop the overall direction and strategic plan for each opportunity.
For more information, visit us at: www.GoldenTriangleInc.com
About Lavish Entertainment, Inc.
Lavish Entertainment, Inc. is a wholly owned subsidiary of Golden Triangle Ventures operating under its Entertainment Division. Currently conducting its business out of Las Vegas, Nevada, the Company started doing business in 2017 and was established with a vision of becoming nationally recognized in concert production. The Company currently has more than 30,000 national followers and nearly 100 team members who have helped Lavish successfully organize some of the most exciting electronic dance music concerts in Las Vegas. Lavish Entertainment strives to produce high-quality and professional events that provide an immersive experience through state-of-the-art production and sound implementation.
Lavish Entertainment is currently developing a flagship entertainment complex called Destino Ranch, which intends to become an ideal outdoor music and festival venue, immersive art installation, tourist attraction and world-renowned destination center. The Company recently secured a purchase agreement to acquire nearly 70 acres of prime and improved land for its Destino Ranch project, which is strategically located in Arizona. The property secured has upgrades that represent a substantial investment totaling nearly $6 million, which has turned this once-vacant land into a beautiful oasis that provides the initial infrastructure needed to begin the development of Destino Ranch.
Forward-Looking Statements
Certain information set forth in this press release contains "forward-looking information," including "future-oriented financial information" and "financial outlook," under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company's business, projects and joint ventures; (iv) execution of the Company's vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company's projects; (vi) completion of the Company's projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company's current customer, supplier and other material agreements; and (viii) future liquidity, working capital and capital requirements. Forward-looking statements are provided to give potential investors the opportunity to understand management's beliefs and opinions in respect to the future so they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance, and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. The Securities and Exchange Commission ("SEC") has provided guidance to issuers regarding the use of social media to disclose material nonpublic information. In this regard, investors and others should note that we announce material financial information on our Company website, www.GoldenTriangleInc.com, in addition to SEC filings, press releases, public conference calls and webcasts. We also use social media to communicate with the public about our Company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, in light of the SEC's guidance, we encourage investors, the media and others interested in our Company to review the information we post on the following U.S. social media channels:
Twitter: www.twitter.com/GTV_Inc
CONTACT INFORMATION:
Golden Triangle Ventures, Inc.
info@GoldenTriangleInc.com
Corporate Communications
IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
$NCL News: Northann Corp Announces Cross-Licensing Agreement with I4F for Digital Printing Technology
ELK GROVE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Northann Corp. (NYSE American: NCL), a leading innovator in 3D-printed home improvement solutions, is pleased to announce a strategic cross-licensing agreement with I4F, a group of companies providing patents and technologies to the flooring industry.
This agreement solidifies a collaborative effort between the two companies to enhance their respective offerings in the digital printing space. Northann Corp's commitment to innovation and quality aligns perfectly with I4F's expertise in digital printing technology, creating a synergy that promises exciting advancements in the flooring industry.
"Intellectual property should not be a barrier to technological and industry advancements; it should be a catalyst for continuous innovation for humanity and the industry as a whole," said Lin Li, CEO of Northann Corp. "Our cross-license agreement with I4F is designed to further democratize this technology and help I4F's digital printing licensees greatly reduce manufacturing costs and entry barriers. After this cross-license agreement, Northann Corp will manufacture its 3D printing ecosystem with digital printing production lines in the United States, drastically reducing production costs, and further solidifying Northann’s foothold within the industry."
About Northann Corp.
Northann specializes in 3D-printed flooring solutions under its flagship brand, "Benchwick." The Company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers its 3D printing ecosystem as an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe. The Company aims to redefine the essence of modern flooring and wall panels by offering stylish, durable, and ecologically conscious solutions.
For more information about Northann, please visit www.northann.com.
Forward-Looking Statement
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For investor and media inquiries, please contact:
Investor Relations
Northann Corp.
Email: ir@northann.com
Phone: +1 (916) 573-3803
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, NY, 10036
Office: (646) 893-5835 x2
Email: info@skylineccg.com
https://www.globenewswire.com/newsroom/ti?nf=OTA4NzE5NCM2MTk0NzA4IzIyNTM4NDA=
https://ml.globenewswire.com/media/Njk0MWU2ZDMtZGE3Yy00OWQ4LWIzZmQtZjE3NTg1ZDA3MTZiLTEyNjUzOTM=/tiny/Northann-Corp-.png
Source: Northann Corp.
$AGBA News February 27, 2024
AGBA Group is Positioned For Hong Kong's Rebounding Macro Environment with Business Refinements and Growth Strategies
https://www.marketwatch.com/press-release/agba-group-is-positioned-for-hong-kong-s-rebounding-macro-environment-with-business-refinements-and-growth-strategies-f566e8f4
$PVGDF - Rauno Perttu, Provenance's CEO, stated, "Having Andy join us as a special advisor at this exciting time for our Company is very helpful. We and Andy see the significant positive impact our Eldorado gold project and similar projects could have on Malheur County.
$TREIF cse $TRUE Treatment AI Passes Medical School Clinical Exam with 92% Success Rate https://finance.yahoo.com/news/treatment-ai-passes-medical-school-123000812.html
$RONN ON RADAR!!! BIG NEWS COMING SOON!!!
$TREIF is pleased to announce that the Company has received funding from The National Institute of Health (“NIH”) to develop a culturally sensitive AI approach for collecting family medical history. https://finance.yahoo.com/news/treatment-com-ai-funded-national-120000374.html
Headline: BestGrowthStocks.Com Issues Comprehensive Evaluation of Movano Inc. $MOVE
https://www.nasdaq.com/press-release/bestgrowthstocks.com-issues-comprehensive-evaluation-of-movano-inc.-2024-04-03
$AGBA - The Company anticipates to receive gross proceeds of approximately $5,128,960 at the closing of the PIPE, in consideration of 7,349,200 Ordinary Shares, and Warrants to purchase up to 1,469,840 Ordinary Shares at a purchase price of $0.70 per Ordinary Share and associated Warrant. Mr. Ng contributes for 53% of the PIPE.
$GDHG News: Golden Heaven Group Holdings Ltd. Enters into a Collaboration Agreement with Nanping City Dacheng Culture Communication Co., Ltd.
NANPING, China, April 2, 2024 /PRNewswire/ -- Golden Heaven Group Holdings Ltd. (the "Company" or "Golden Heaven") (Nasdaq: GDHG), an amusement park operator in China, today announced that on March 29, 2024, it entered into a collaboration agreement (the "Agreement") with Nanping City Dacheng Culture Communication Co., Ltd. ("Dacheng Culture").
Under the Agreement, Golden Heaven has agreed to lease certain land and property to Dacheng Culture to host a range of activities, including wedding photography, family photography, marriage proposal planning, Hanfu (traditional Chinese clothing) photography, and various celebratory events. Dacheng Culture has agreed to compensate the Company with an aggregate lease payment of RMB6 million, payable quarterly, over the contract period, which extends from March 29, 2024 to March 28, 2025.
Mr. Jin Xu, the CEO and Chairman of the Company, commented, "As previously disclosed on March 19, 2024, we entered into a similar collaboration agreement with Zigong City Dragon Culture & Arts Co. Ltd. These collaboration agreements are designed to leverage our park locations and family-oriented attractions, enhance site utilization and strengthen bonds with our guests. The diverse activities that Dacheng Culture plans to introduce to our parks are expected to attract more guests, elevate the guest experience and add to our revenue. We are enthusiastic about embarking on this venture and future collaborations."
About Golden Heaven Group Holdings Ltd.
Golden Heaven Group Holdings Ltd. manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. With approximately 426,560 square meters of land in the aggregate, these parks are located in geographically diverse markets across the south of China and collectively offer approximately 139 rides and attractions. Due to the geographical locations of the parks and the ease of travel, the parks are easily accessible to an aggregate population of approximately 21 million people. Since September 30, 2023, Mangshi Jinsheng Amusement Park, which is one of the six parks, has been temporarily closed. The parks provide a wide range of exciting and entertaining experiences, including thrilling rides, family-friendly attractions, water attractions, gourmet festivals, circus performances, and high-tech facilities. For more information, please visit the Company's website at https://ir.jsyoule.com/.
Forward-Looking Statements
This press release contains "forward-looking statements". Forward-looking statements reflect our current view about future events. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "could," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "propose," "potential," "continue" or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the U.S. Securities and Exchange Commission.
For investor and media inquiries, please contact:
Golden Heaven Group Holdings Ltd.
Email: group@jsyoule.com
Ascent Investor Relations LLC
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
https://c212.net/c/img/favicon.png?sn=CN77335&sd=2024-04-02 View original content:https://www.prnewswire.com/news-releases/golden-heaven-group-holdings-ltd-enters-into-a-collaboration-agreement-with-nanping-city-dacheng-culture-communication-co-ltd-302105015.html
SOURCE Golden Heaven Group Holdings Ltd.
$TREIF cse: $TRUE Treatment AI is quickly becoming the best assistant a doctor or nurse could ever ask for https://www.thebullreport.com/true/
$TREIF CSE : $TRUE Breaking News! http://Treatment.com AI Funded by the National Institute of Health to Develop a Culturally Sensitive AI Approach to Health Equity https://finance.yahoo.com/news/treatment-com-ai-funded-national-120000374.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr… via
@YahooFinance $MSFT $NVDA $AAPL $TSLA
CSE $TRUE, OTC: $TREIF is pleased to announce that it’s AI medical information support platform was used in the “Objective Structured Clinical Examination” (“OSCE”), a standard clinical exam of diagnostic aptitude at medical and nursing schools, passing the exam with a 92% success rate. https://finance.yahoo.com/news/treatment-ai-passes-medical-school-123000812.html
$GTVH News: Golden Triangle Ventures, Inc. Re-Engages IBN for Corporate Communication Initiatives
LOS ANGELES, March 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Golden Triangle Ventures, Inc. (OTC: GTVH) (“GTV” or the “Company”) announces that it has selected IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its corporate communications initiatives. Having previously played an integral role in GTV's early accomplishments throughout 2021, IBN's renewed involvement in the company signifies a paramount advancement toward its objective of maximizing shareholder value and adeptly conveying the company's narrative and strategic initiatives.
As part of the Client Partner relationship, IBN will leverage its investor-based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools to generate greater awareness for Golden Triangle Ventures.
With 18+ years of experience assisting 500+ client partners to improve communications within the investment community, and a sizable family of 60+ trusted brands, IBN has amassed a collective audience that includes millions of social media followers. IBN is uniquely positioned to provide Golden Triangle Ventures the solutions needed to reach a wide audience of investors, journalists and the general public.
Steffan Dalsgaard, CEO of Golden Triangle Ventures, emphasizes, "As we embark on our most ambitious projects within GTV, we're actively intensifying our collaboration with IBN. Their outstanding performance and proven success in our prior engagement throughout 2021 unequivocally affirm our decision to reengage. We entrust IBN's expertise to effectively amplify our achievements and bolster our presence as we are now undertaking some of the biggest projects of our careers.”
To learn more about Golden Triangle Ventures, please visit the company’s corporate newsroom: https://IBN.fm/GTVH
About IBN
IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
About Golden Triangle Ventures, Inc.
Golden Triangle Ventures, Inc. or “GTV” is a multifaceted consulting Company, which operates as the parent business pursuing ventures in the health, entertainment and technology sectors, along with others that provide synergistic value to these three core divisions. The Company aims to purchase, acquire and/or joint venture with established entities within these areas of business. The goods and services represented are driven by innovators who have passion and commitment in these marketplaces. The Company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. The three points of the Golden Triangle exclusively represent the three sectors in which this Company aims to do business. Golden Triangle Ventures is highly focused on acquiring a well-diversified portfolio of companies under one umbrella, which are all managed and owned by the Company. An amazing team of professionals support each division and continue to help the Company grow daily. Being a publicly traded Company gives the ability to provide the support needed to help each subsidiary grow into the business management believes it can and will become.
Golden Triangle Ventures’ business model is supported by the drive for vertical integration to cut costs and maximize margins. Management strives to acquire entities and assets that they fully understand, which maintain the prospect for long-term exponential growth. The mission is to provide the necessary resources for each subsidiary to generate profit, and then allow them to leverage each other and maximize economic impact. In addition, GTV provides a professional corporate representation service to different companies in these sectors while consulting on a variety of different business development objectives.
The backbone of this business is truly a team of professional advisors looking to help companies with a multitude of corporate objectives. With an extensive Rolodex of relationships, management can help with a dynamic range of project obstacles while maintaining a quality service for each client the Company represents. No matter what the needs are, the team involved can help facilitate many different transactions successfully for all parties involved. The network of relationships expands to industry experts who can assist with project management, product sourcing, industrial agriculture project implementation and so much more. Golden Triangle Ventures develops strategies and detailed plans that are custom-tailored to each corporate need and objective in all areas of business.
The GTV business model is focused on the following core group of interests:
Acquisitions / Assets / Holdings - The Company currently owns a unique portfolio of companies that are all being developed and supported by GTV, each holding a common goal of making a positive impact in the industry in which they operate.
Services - Services are deployed through Golden Triangle Ventures to assist all the unique opportunities within its operation. The Company also offers its services to select opportunities that could develop synergistic value within the relationship between both companies through the result of its efforts.
Investments - Management identifies high-value opportunities and provides capital investments in several companies and projects being developed. Each investment is complemented by a hands-on approach of helping to develop the overall direction and strategic plan for each opportunity.
For more information, visit us at: http://www.GoldenTriangleInc.com
About Lavish Entertainment, Inc.
Lavish Entertainment, Inc. is a wholly-owned subsidiary of Golden Triangle Ventures operating under its Entertainment Division. Currently conducting its business out of Las Vegas, Nevada, the Company started doing business in 2017 and was established with a vision of becoming nationally recognized in concert production. The Company currently has more than 30,000 national followers and nearly 100 team members who have helped Lavish successfully organize some of the most exciting electronic dance music concerts in Las Vegas. Lavish Entertainment strives to produce high-quality and professional events that provide an immersive experience through state-of-the-art production and sound implementation.
Lavish Entertainment is currently developing a flagship entertainment complex called Destino Ranch which intends to become an ideal outdoor music and festival venue, immersive art installation, tourist attraction and world-renowned destination center. The company recently secured a purchase agreement to acquire nearly 70 acres of prime and improved land for its Destino Ranch project which is strategically located in Arizona. The property secured has upgrades that represent a substantial investment totaling nearly $6 million, which has turned this once-vacant land into a beautiful oasis that provides the initial infrastructure needed to begin the development of Destino Ranch.
Lavish Entertainment recently appointed Marco Antonio Moreno as its new president and chief operations officer. Moreno is the founder, senior designer and lead project manager for ABI Create, L.L.C. (“ABI”). Formed in 2015, and based out of Phoenix, Arizona, ABI is a complete-service event management and production firm offering:
Event Organization, Management, Production and Logistics
Site Planning and Permitting
Construction and Contracting
Custom Design and Fabrication
And More
ABI Create has successfully implemented its corporate vision of delivering high-fidelity production to large-scale installations that span major music festivals, major sporting events and notable conventions across the United States. Notable collaborative work samples include projects produced for:
NFL Super Bowl
San Diego & New York Comic-Con
EDC & Camp EDC and Other Insomniac Events
Bonnaroo Music Festival
The Waste Management Phoenix Open and Arnold Palmer Invitational
Burning Man
More information on Moreno, along with his collaborators, partners and team, can be found at https://abicreate.com/ or @marco.a.moreno
ABI was a crucial team member in the production of Lavish Entertainment’s Playa Playground New Year’s event (“Playa”). Held on Dec. 31, 2021, Playa was an auspicious and grand-scale Burning-Man-style music festival staged in downtown Las Vegas that redefined the level of event that Lavish can provide. Due to the role ABI played in the execution of Playa, the CEO of Golden Triangle Ventures, Steffan Dalsgaard, handpicked Moreno to lead the new vision of Lavish and contribute to the Company’s overarching business goal of becoming an industry-leading, innovative and, at-the-forefront music and arts entertainment production company.
Forward-Looking Statements
Certain information set forth in this press release contains "forward-looking information," including "future-oriented financial information" and "financial outlook," under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company's business, projects and joint ventures; (iv) execution of the Company's vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company's projects; (vi) completion of the Company's projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company's current customer, supplier and other material agreements; and (viii) future liquidity, working capital and capital requirements. Forward-looking statements are provided to give potential investors the opportunity to understand management's beliefs and opinions in respect to the future so they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance, and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. The Securities and Exchange Commission ("SEC") has provided guidance to issuers regarding the use of social media to disclose material nonpublic information. In this regard, investors and others should note that we announce material financial information on our Company website, www.GoldenTriangleInc.com, in addition to SEC filings, press releases, public conference calls and webcasts. We also use social media to communicate with the public about our Company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, in light of the SEC's guidance, we encourage investors, the media and others interested in our Company to review the information we post on the following U.S. social media channels:
Twitter: www.twitter.com/GTV_Inc
CONTACT INFORMATION:
Golden Triangle Ventures, Inc.
info@GoldenTriangleInc.com
Corporate Communications
IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
$IQST - iQSTEL profiting heavy lately 💪 Just brought in $250Ms in the black. Thinking $1B next, could be next Verizon up in here. Little teamwork from us small guys could boost it past $1 real quick 📈Then we all cashing out fat!
$TWOH is hopeful for a market rebound from its recent downturn and aims to deliver robust returns to investors starting as soon as the overhanging shares from the previous finance partner are exhausted. https://twohandsgroup.com/blog/twoh-weathering-the-storm
$IFBC Key Investment Factors #IFBC
Growing – Dino Luzzi grew revenues from $38,137 in 2021 to $128,430 in 2022. That’s a 238% increase YoY. This shows the product is in demand, and that demand is growing.
Taste – Dino Luzzi beats out the big guys in blind taste tests. That’s no small feat. While brand recognition remains strong
Expansion Plans – IFBC has developed a significant prime retail space in Western Beef, a New-York based grocer. With 22 warehouse style stores and locations across the Northeastern US (and a few Florida outlets), Dino Luzzi has plenty of shelves to grow into. Additionally, the company has recently partnered with Key Food Fresh and Iavarone Bros. https://microcaps.com/a-ground-floor-opportunity-in-a-growing-energy-drink-company/
Followers
|
525
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
45886
|
Created
|
02/21/10
|
Type
|
Free
|
Moderator MaxPowerLove$Ihub | |||
Assistants mick Ask$lapper k124Inv RoadRunner3 |
Welcome!
Sad =( Not Funny! But it's True!
Remember, The OTC Market is like Vegas! Treat trading & investing in every penny stocks like Casino gambling!
Check out some of our picks & results in the past:
Recent Plays:
Le2dynasty: Alerted for CBYI in late March @ the point when the stock was at no bid. A few weeks later the PPS reached .0004s (400% gain)
Le2dynasty: Alerted for GRPS (together with KGRI, CBYI) @ .0001s on May 17th...On May 23rd the PPS touched .0012s (1,200% gain)
Le2dynasty: Alerted for CBYI @ .0001s on May 23rd -- early morning & within a few hours, the PPS reached .0003s with mega trading volume-- (71 mil. total trading vol. with 99% buyin' vol.) (300% gain)
Le2dynasty: Alerted for CBYI @ .0002s on May 24rd -- early morning & immediately, the PPS reached .0004s with mega trading volume -- (more than 100 mil. total trading vol. CBYI was the top in top trading vol. on this day) (100% gain)
Le2dynasty: Alerted for EMLL @ .0002s on July 2nd -- early morning & the PPS reached .0004s with mega trading volume -- (more than 260 mil. total trading vol. EMLL became the top in top trading vol. & top in breakout board on this day) (50% gain)
Le2dynasty: Alerted for HIRU @ .0001s on July 3rd & on July 9, HIRU reached .0006s with mega trading volume (600% gain)
Le2dynasty: Alerted for IMDS @.0005s on July 9 @ the pt. when the total trading vol. is below 80 mil. Within 50 minutes later, the PPS reached .0009s, with more than 245 mil. total trading vol. (80% gain) in less than 1 hr. On July 10th another alert was sent out to remind traders/investors & on July 12th, the PPS reached .0026s..that is more than (500% gain) since July 9 alert.
Le2dynasty: Alerted for NVAE in early moring @ the pt. when the stock was @ no bid. PPS then reached .0003s (200% again) with a mega trading vol. (end the trading day with more than 230 mil total trading vol.). Unfortunately, the the stock dropped back to .0001 at closing.
BurntOrang3: : 400-500% gains off of DRGI after the alert
BurntOrang3: : Over 100% gains after my AUCI alert
**** Attention: Mods, Please don't edit the ibox w/o asking me first, b/c there are some kind of coding problems here ...and the IH Greeks ...Especially IH Greek (Dave) had spent a lot of time fixing this. Thank you Dave and thank all the mods here as well ****
Our Associates:
TheKingPennyStock
Daily 000X Plays
Monster Day Traders
Pinky With Potential!
BOTTOM PLAYS! CHART TECH! RESEARCH! STRATEGIES!
"A Dawgg"
Billionaire Boys Club Member Forum (BBCMF)
THE WALL STREET CLUB
$THE WAVE
THE BLUE EXCHANGE
ALERTS, CHARTS, & HOT STOCKS
Momentum Players
Momentum Runners
MOMO'S BREAKOUT BOARD
STOCKGOODIES PLAYS OF THE WEEK
Welcome To The Zoo
~~~TEFFY''S~~~HOT~~~PROFILED~~~PICKS~~~
Another Winning Trade
CASH COW
EZ Traders Forum
NO BRAINERS
StocksDiva Bio Bin
Pinto Beans and Money Making Stock Picks
PINKSHEET Breakout Board!!!
Picks For Every Play
Penny Stock Millionaire
The Van Scan
UNDERVALUED PENNY STOCKS
The Penny Stock Grow Room
Wowza board
Disclaimer: We are not investment advisors. We recommend investors to do their own due diligence. Never invest in any stock unless you can afford to lose your entire investment. Opinions expressed on this board are only opinions.
PER IHUB MGMT |
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Posts Today
|
0
|
Posts (Total)
|
45886
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |